Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Stanford University
Hoffmann-La Roche
University of Nebraska
Ohio State University Comprehensive Cancer Center
Tanabe Pharma America, Inc.
Massive Bio, Inc.
Novelty Nobility, Inc.
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Jonsson Comprehensive Cancer Center
Turning Point Therapeutics, Inc.
University of Pittsburgh
PharmaMar
Nuvation Bio Inc.
British Columbia Cancer Agency
Hoffmann-La Roche
Instituto do Cancer do Estado de São Paulo
Hutchmed
Nanjing First Hospital, Nanjing Medical University
EpicentRx, Inc.
Vastra Gotaland Region
Hoffmann-La Roche
University of California, San Francisco
Peking Union Medical College Hospital
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
University of Maryland, Baltimore
Eli Lilly and Company
Stanford University
Stanford University
Merck Sharp & Dohme LLC
Tel-Aviv Sourasky Medical Center